Edwards Lifesciences Corp. expects revenues from its transcatheter mitral and tricuspid valve therapies (TMTT) to double in 2020.
Edwards' is projecting TMTT revenue will be under $40m for all of 2019, but climb to $80m in 2020 after the company brings the Pascal mitral valve repair device to...